Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.

Annals of the rheumatic diseases·2023

Same author

Effectiveness and safety of rituximab in Takayasu arteritis: a multicenter retrospective study.

Joint bone spine·2023

Same author

European Stroke Organisation (ESO) guidelines on Primary Angiitis of the Central Nervous System (PACNS).

European stroke journal·2023

Same author

Polymyalgia rheumatica.

Lancet (London, England)·2023

Same author

Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study.

Arthritis research & therapy·2023

Same author

Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: a matched cross-sectional study.

RMD open·2023

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Multidisciplinary focus on cyclosporin A.

Carlo Salvarani¹, Luigi Boiardi, Pierluigi Macchioni

¹Unit of Rheumatology, Hospital of Reggio Emilia, 42100 Reggio Emilia, Italy. salvarani.carlo@asmn.re.it

The Journal of Rheumatology. Supplement

|August 8, 2009

Summary

Cyclosporin A effectively treats severe psoriasis and psoriatic arthritis (PsA). Studies show its efficacy in peripheral arthritis, with long-term safety and persistent benefits observed.

Related Experiment Videos

Last Updated: Jun 21, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Area of Science:

Immunology
Dermatology
Rheumatology

Background:

Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory conditions.
Cyclosporin A (CsA) is an immunosuppressive drug with known efficacy in treating severe cutaneous psoriasis.

Purpose of the Study:

To review the efficacy and safety of Cyclosporin A (CsA) in managing psoriatic arthritis (PsA).
To explore the therapeutic strategies and potential mechanisms of action for CsA in PsA and psoriasis.

Main Methods:

Review of open prospective studies on CsA for PsA.
Analysis of three controlled trials comparing CsA to other disease-modifying antirheumatic drugs (DMARDs).
Examination of long-term safety and efficacy data for CsA in PsA patients.

Main Results:

CsA demonstrates short-term efficacy in PsA, particularly for peripheral arthritis.
Controlled trials support CsA's effectiveness against other DMARDs in PsA.
Long-term studies confirm persistent efficacy and safety of CsA in PsA.
CsA's anti-angiogenic properties, via blocking vascular endothelial growth factor, may contribute to its benefits in PsA and psoriasis.

Conclusions:

Cyclosporin A is an effective treatment option for psoriatic arthritis (PsA) and severe cutaneous psoriasis.
While effective for peripheral arthritis, CsA's efficacy for dactylitis and axial disease requires further investigation.
Long-term use of CsA in PsA is associated with sustained efficacy and a favorable safety profile.